MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...

A prostate cancer committee has been accused of exaggerating the risks of screening. Advisers to Wes Streeting, the Health Secretary, rejected calls to offer targeted testing in November, arguing that ...

Wolinsky is a Chicago-based medical journalist and publisher of The Active Surveillor, a Substack newsletter that covers lower-risk prostate cancer and active surveillance. In 2002, at age 55, I ...

Prostate cancer screenings slash the risk of dying from the disease in the following decades, according to new research. The screening measures the amount of prostate-specific antigen (PSA) in men’s ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

HUNTSVILLE, Ala. (WHNT) — Prostate cancer is the most common cancer in men, with about 1-in-8 expected to be diagnosed in their lifetime. However, chances of survival are good when it’s caught early.

For men, a new urine test is improving prostate cancer detection. Men know about the PSA test but there's another test, the "mi-prostate score" or MIPS. It's been available since 2013. It combines PSA ...